EPO (erythropoietin) is a well-known original drug in clinical practice, with established brands like Epogen, Procrit, and Eprex being the most familiar names. Roche later introduced the long-acting Mircera (methoxydiol recombinant human erythropoietin). Simply put, it's a recombinant glycoprotein hormone that specifically tricks the bone marrow into producing more red blood cells. This is used to treat anemia caused by chronic kidney disease, chemotherapy, or zidovudine, and can also help conserve blood before elective surgery, reducing the need for transfusions.
Core Advantages:
Clear target mechanism; specifically binds to the EPOR receptor, inhibiting erythroid progenitor cell apoptosis and promoting erythrocyte maturation. Extensive publicly available literature provides references for hematopoietic-related models, making experimental protocols easier to replicate.
In addition to hematopoietic function, it can activate multiple antioxidant and anti-apoptotic pathways, making it suitable for expanding research directions such as hypoxia injury, ischemic tissue protection, and nerve cell damage repair. A single reagent can support multi-dimensional research projects.
Reputable brands have strict batch quality control standards, ensuring stable purity, endotoxin levels, and bioactivity indicators with minimal batch-to-batch fluctuations. This also guarantees better data reproducibility in long-term parallel experiments.
Mature expression technology ensures protein folding closely matches the natural conformation, resulting in stable receptor affinity and activity. It is suitable for various administration methods, including cell culture, intraperitoneal/intravenous administration in animals, and has a user-friendly operational threshold.
Objective drawbacks:
The black box warning about EPO is not to be underestimated-it can indeed increase the risk of death, myocardial infarction, stroke, venous thrombosis, and tumor progression. The most common and troublesome clinical consequence is a spike in blood pressure, occurring in nearly 30% of cases. Some patients experience headaches, confusion, or even cerebral hemorrhage while receiving EPO, making it unsafe for those with uncontrolled blood pressure.
Another problem that keeps hematologists up at night is pure erythrocyte aplasia (PRCA)-the sudden appearance of antibodies that neutralize EPO in the patient's body prevents red blood cell production, causing a significant drop in reticulocyte count and worsening anemia. Once this occurs, the drug must be permanently discontinued, and switching to other ESAs is not possible due to potential antibody cross-reactivity. Cancer patients need to be extremely cautious. Studies show that in some patients with solid tumors and hematological malignancies, EPO not only fails to prolong survival but may even accelerate tumor growth.
Price-wise, original drugs are never cheap, especially long-acting formulations. Reimbursement rates and indication restrictions vary by region, and the out-of-pocket costs can be a significant burden for ordinary families.
Storage Conditions
Unopened original packaging: Refrigerate at 2–8℃, protected from light. Do not freeze or shake. Discard any bottles that have been frozen once, have cloudy solutions with flocculent material, or have dented rubber stoppers. Epoetin multi-dose vials can be kept in the refrigerator for a maximum of 21 days after opening; discard them after that. Single-dose vials should not be kept even if only a small amount remains. The same applies to Aranesp pre-filled pens: refrigerate in the original box, protected from light. Briefly moving them in and out at room temperature is acceptable, but avoid direct sunlight and warming them by hand. The entire transportation process is under cold chain. Upon arrival, immediately touch the bottle; do not use any that are frozen.
Precautions:
For laboratory research use only. Human application is strictly prohibited. A complete disclaimer must be included on the product page.
For reconstitution, use neutral sterile PBS with a compatible protein carrier. Direct dilution with pure water over a long period can cause protein adsorption to the tube wall and loss of activity.
Concentration gradient pre-experiments must be conducted before formal experiments. Do not directly copy literature dosages to avoid excessive red blood cell proliferation and additional experimental interference.
Perform aseptic techniques throughout the entire process. Protein contamination leading to microbial growth not only destroys activity but also causes metabolic impurities to directly contaminate the cell system.
During continuous dosing in animal experiments, it is recommended to monitor blood counts regularly and adjust the dosing regimen promptly to avoid complications caused by high blood viscosity.
Distinguish between regular EPO and the long-acting modified version. Their pharmacokinetic differences are significant; dosing regimens cannot be directly interchanged.
Hot Tags: scientific research experimental peptide epo (branded) cas: 113427-24-0, China scientific research experimental peptide epo (branded) cas: 113427-24-0 manufacturers, suppliers, factory
